This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Pfizer Divesting Zoetis, Returning Human Health Focus

Pfizer Inc. ( PFE ) will be divesting Zoetis, which makes vaccines and drugs for pets, cattle, swine and other farm animals. The IPO hopes to raise up to $2.2 billion for the animal-medicine and vaccine company and is another attempt by Pfizer to focus on its core human-health businesses going forward.

EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Pfizer sold Vevey, an infant nutrition business, to Nestle SA for $11.9 billion last April. Bristol-Myers Squibb Co. ( BMY) has also participated in divesting activity, selling Mead Johnson Nutrition Co. ( MJN).  Since the sale, both stocks have gained 60% and 160% respectively.

Zoetis’s IPO is expected to price on the NYSE on January 31st under the ticker ZTS. Pfizer will continue to hold 414 million class B shares and will have 83% control over Zoetis. 81.6 million Class A shares will be on the market for $22-25 each.


Pfizer is trying to trim the fat and focus on its core business. CEO Ian Read is shrinking the drugmaker with these divestures, helping spur future growth and increasing returns for shareholders. A divesture, like increasing dividends or buying back stock, will return value to shareholders.

Zoetis is the biggest animal-medicine and vaccine company in the world by revenue. 

Written by Kapitall's Nick Sousa

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.03 -2.90%
FB $117.52 7.90%
GOOG $691.20 -2.10%
TSLA $247.54 -1.60%
YHOO $36.58 -1.00%


Chart of I:DJI
DOW 17,830.76 -210.79 -1.17%
S&P 500 2,075.81 -19.34 -0.92%
NASDAQ 4,805.2910 -57.85 -1.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs